DILIPKUMAR JOSHI: Open Payments
NPI 1669565537 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,146 in 61 payments from 14 companies in 2025. Trend: 2023 $731 · 2024 $1,050 · 2025 $1,146
Food & beverage: $1,146
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 8 | $173 |
| Otsuka America Pharmaceutical, Inc. | 10 | $167 |
| Alkermes, Inc. | 7 | $147 |
| Vanda Pharmaceuticals Inc. | 8 | $130 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $120 |
| Lundbeck LLC | 6 | $117 |
| ABBVIE INC. | 4 | $72 |
| Supernus Pharmaceuticals, Inc. | 4 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Braeburn Inc. | 2 | $31 |
Products named: COBENFY, REXULTI, LYBALVI, ABILIFY ASIMTUFII, CAPLYTA, VRAYLAR, FANAPT, Qelbree.
Industry payments across DE — which companies pay providers there.
